3H-1,2-Benzoxaphosphepine 2-oxides as selective inhibitors of carbonic anhydrase IX and XII

References

• Supuran CT. Carbonic anhydrases and metabolism. Metabolites. 2018;21:25.
   Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J. 2016;473(14):2023–2032.
   PubMedGoogle Scholar
• (a) Singh S, Lomelino CL, Mboge MY, Frost SC, McKenna R. Cancer drug development of carbonic anhydrase inhibitors beyond the active site. Molecules. 2018;23:1045.
   Google Scholar
  (b) Angeli A, Carta F, Nocentini A, Winum JY, Zalubovskis R, Akdemir A, Onnis V, Eldehna WM, Capasso C, Simone G, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites. 2020;10:412.
   PubMed Web of Science ®Google Scholar
• (a) Winum J-Y, Rami M, Scozzafava A, Montero JL, Supuran C. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev. 2008;28:445–463.
   Google Scholar
  (b) McDonald PC, Winum J-Y, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012;3:84–97.
   PubMed Web of Science ®Google Scholar
  (c) McDonald PC, Chafe SC, Supuran CT, Dedhar S. Cancer therapeutic targeting of hypoxia induced carbonic anhydrase ix: from bench to bedside. Cancers. 2022;14:3297.
   PubMed Web of Science ®Google Scholar
• Watson PH, Chia SK, Wykoff CC, Han C, Leek RD, Sly WS, Gatter KC, Ratcliffe P, Harris AL. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer. 2003;88(7):1065–1070.
   PubMed Web of Science ®Google Scholar
• (a) Ozensoy Guler O, De Simone G, Supuran CT. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr Med Chem. 2010;17:1516–1526.
   Google Scholar
  (b) Kciuk M, Gielecińska A, Mujwar S, Mojzych M, Marciniak B, Drozda R, Kontek R. Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. J Enzyme Inhib Med Chem. 2022;37:1278–1298.
   PubMed Web of Science ®Google Scholar
• (a) Alterio V, Di Fiore A, D’Ambrosio K, Supuran CT, De Simone G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112:4421–4468.
   Google Scholar
  (b) Aggarwal M, Kondeti B, McKenna R. Insights towards sulfonamide drug specificity in α-carbonic anhydrases. Bioorg Med Chem. 2013;21:1526–1533.
   PubMed Web of Science ®Google Scholar
• Žalubovskis R. In a search for selective inhibitors of carbonic anhydrases: coumarin and its bioisosteres – synthesis and derivatization. Chem Heterocycl Comp. 2015;51(7):607–612.
   Web of Science ®Google Scholar
• (a) Maresca A, Temperini C, Vu H, Pham NB, Poulsen S-A, Scozzafava A, Quinn RJ, Supuran CT. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc. 2009;131:3057–3062. (b) Supuran CT. Coumarin carbonic anhydrase inhibitors from natural sources. J Enzyme Inhib Med Chem. 2020;35:1462–1470.
   Google Scholar
• (a) Bonneau A, Maresca A, Winum J-Y, Supuran CT. Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2013;28:397–401.
   Google Scholar
  (b) Sharma A, Tiwari M, Supuran CT. Novel coumarins and benzocoumarins acting as isoform-selective inhibitors against the tumor-associated carbonic anhydrase IX. J Enzyme Inhib Med Chem. 2014;29:292–296.
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Pochet L, Masereel B, Scozzafava A, Supuran CT. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010;53(1):335–344.
   PubMed Web of Science ®Google Scholar
• (a) Tars K, Vullo D, Kazaks A, Leitans J, Lends A, Grandane A, Zalubovskis R, Scozzafava A, Supuran CT. Sulfocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX/XII and of human thioredoxin reductase. J Med Chem. 2013;56(1):293–300.
   PubMed Web of Science ®Google Scholar
  (b) Krasavin M, Žalubovskis R, Grandāne A, Domračeva I, Zhmurov P, Supuran CT. Sulfocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX/XII and of human thioredoxin reductase. J Enzyme Inhib Med Chem. 2020;35:506–510.
   PubMed Web of Science ®Google Scholar
• (a) Tanc M, Carta F, Bozdag M, Scozzafava A, Supuran CT. 7-Substituted-sulfocoumarins are isoform-selective, potent carbonic anhydrase II inhibitors. Bioorg Med Chem. 2013;21:4502–4510.
   Google Scholar
  (b) Nocentini A, Ceruso M, Carta F, Supuran CT. 7-Aryl-triazolyl-substituted sulfocoumarins are potent, selective inhibitors of the tumor-associated carbonic anhydrase IX and XII. J Enzyme Inhib Med Chem. 2016;31:1226–1233.
   PubMed Web of Science ®Google Scholar
• (a) Grandane A, Tanc M, Di Cesare Mannelli L, Carta F, Ghelardini C, Žalubovskis R, Supuran CT. 6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells. J Med Chem. 2015;58:3975–3983.
   Google Scholar
  (b) Grandane A, Tanc M, Žalubovskis R, Supuran CT. Synthesis of 6-aryl-substituted sulfocoumarins and investigation of their carbonic anhydrase inhibitory action. Bioorg Med Chem. 2015;23:1430–1436.
   PubMed Web of Science ®Google Scholar
  (c) Grandane A, Tanc M, Zalubovskis R, Supuran CT. 6-Triazolyl-substituted sulfocoumarins are potent, selective inhibitors of the tumor-associated carbonic anhydrases IX and XII. Bioorg Med Chem Lett. 2014;24:1256–1260.
   PubMed Web of Science ®Google Scholar
  (d) Grandane A, Tanc M, Zalubovskis R, Supuran CT. Synthesis of 6-tetrazolyl-substituted sulfocoumarins acting as highly potent and selective inhibitors of the tumor-associated carbonic anhydrase isoforms IX and XII. Bioorg Med Chem. 2014;22:1522–1528.
   PubMed Web of Science ®Google Scholar
• Podolski-Renić A, Dinić J, Stanković T, Jovanović M, Ramović A, Pustenko A, Žalubovskis R, Pešić M. Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance. Eur J Pharm Sci. 2019;138:105012.
   PubMed Web of Science ®Google Scholar
• (a) Pustenko A, Stepanovs D, Žalubovskis R, Vullo D, Kazaks A, Leitans J, Tars K, Supuran CT. 3H-1,2-benzoxathiepine 2,2-dioxides: a new class of isoform-selective carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2017;32:767–775.
   Google Scholar
  (b) Pustenko A, Nocentini A, Balašova A, Alafeefy A, Krasavin M, Žalubovskis R, Supuran CT. Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2020;35:245–254.
   PubMed Web of Science ®Google Scholar
  (c) Pustenko A, Nocentini A, Balašova A, Krasavin M, Žalubovskis R, Supuran CT. 7-Acylamino-3H-1,2-benzoxathiepine 2,2-dioxides as new isoform-selective carbonic anhydrase IX and XII inhibitors. J Enzyme Inhib Med Chem. 2020;35:650–656.
   PubMed Web of Science ®Google Scholar
• (a) Rodriguez JB, Gallo-Rodriguez C. The role of the phosphorus atom in drug design. Chem Med Chem. 2019;14:190–216.
   Google Scholar
  (b) Ceradini D, Shubin K. New methods for the synthesis of phosphono-δ-lactones (microreview). Chem Heterocycl Compd. 2021;57:1167–1169.
   Web of Science ®Google Scholar
  (c) Balašova A, Žalubovskis R. Synthetic methods toward phosphacoumarins (microreview). Chem Heterocycl Comp. 2022;58:310–312.
   Web of Science ®Google Scholar
• (a) Bonnac L, Innocenti, A, Winum J-Y, Casini A, Montero JL, Scozzafava A, Barragan V, Supuran CT. Carbonic anhydrase inhibitors: aliphatic N-phosphorylated sulfamates—a novel zinc-anchoring group leading to nanomolar inhibitors. J Enzyme Inhib Med Chem. 2004;19:275–278.
   Google Scholar
  (b) Winum J-Y, Innocenti A, Gagnard V, Montero JL, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005;15:1683–1686.
   PubMed Web of Science ®Google Scholar
  (c) Gülçin İ, Trofimov B, Kaya R, Taslimi P, Sobenina L, Schmidt E, Petrova O, Malysheva S, Gusarova N, Farzaliyev V, et al. Synthesis of nitrogen, phosphorus, selenium and sulfur-containing heterocyclic compounds – Determination of their carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and α-glycosidase inhibition properties. Bioorg Chem. 2020;103:104171.
   PubMed Web of Science ®Google Scholar
  (d) Nocentini A, Alterio V, Bua S, Micheli L, Esposito D, Buonanno M, Bartolucci G, Osman SM, ALOthman ZA, Cirilli R, et al. Phenyl(thio)phosphon(amid)ate benzenesulfonamides as potent and selective inhibitors of human carbonic anhydrases II and VII counteract allodynia in a mouse model of oxaliplatin-induced neuropathy. J Med Chem. 2020;63:5185–5200.
   PubMed Web of Science ®Google Scholar
• Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem. 2011;54(8):2529–2591.
   PubMed Web of Science ®Google Scholar
• Hirschbeck V, Fleischer I. Synthesis of benzofuranones via palladium-catalyzed intramolecular alkoxycarbonylation of alkenylphenols. Chemistry. 2018;24(12):2854–2857.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sigman MS. Development of a general Pd(II)-catalyzed intermolecular hydroalkoxylation reaction of vinylphenols by using a sacrificial alcohol as the hydride source. Org Lett. 2006;8(24):5557–5560.
   PubMed Web of Science ®Google Scholar
• Fleischer I, Pospech J. Brønsted acid-catalyzed hydroarylation of activated olefins. RSC Adv. 2015;5(1):493–496.
   Web of Science ®Google Scholar
• Fourgeaud P, Midrier C, Vors J-P, Volle J-N, Pirat J-L, Virieux D. Oxaphospholene and oxaphosphinene heterocycles via RCM using unsymmetrical phosphonates or functional phosphinates. Tetrahedron. 2010;66(3):758–764.
   Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem. 1971;246(8):2561–2573.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT, Ilies MA, Scozzafava A. Carbonic anhydrase inhibitors. Part 29. Interaction of isozymes I, II and IV with benzolamide-like derivatives. Bioorg Med Chem. 1998;33:739–752.
   Google Scholar
  (b) Sentürk M, Gülçin I, Daştan A, Küfrevioğlu OI, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009;17:3207–3211.
   PubMed Web of Science ®Google Scholar
• Leitans J, Kazaks A, Balode A, Ivanova J, Zalubovskis R, Supuran CT, Tars K. Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX. J Med Chem. 2015;58(22):9004–9009.
   PubMed Web of Science ®Google Scholar
• (a) Nocentini A, Angeli A, Carta F, Winum J-Y, Zalubovskis R, Carradori S, Capasso C, Donald WA, Supuran CT. N-substituted and ring opened saccharin derivatives selectively inhibit transmembrane, tumor-associated carbonic anhydrases IX and XII. J Enzyme Inhib Med Chem. 2021;36(1):561–580.
   PubMed Web of Science ®Google Scholar
  (b) Pustenko A, Nocentini A, Gratteri P, Bonardi A, Vozny I, Žalubovskis R, Supuran CT. The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2020;35:1011–1020.
   PubMed Web of Science ®Google Scholar
  (c) Ivanova J, Carta F, Vullo D, Leitans J, Kazaks A, Tars K, Žalubovskis R, Supuran CT. N-substituted and ring opened saccharin derivatives selectively inhibit transmembrane, tumor-associated carbonic anhydrases IX and XII. Bioorg Med Chem. 2017;25:3583–3589.
   PubMed Web of Science ®Google Scholar
• Schmickl CN, Owens RL, Orr JE, Edwards BA, Malhotra A. Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence. BMJ Open Resp Res. 2020;7(1):e000557.
   PubMed Web of Science ®Google Scholar
• Bonardi A, Nocentini A, Bua S, Combs J, Lomelino C, Andring J, Lucarini L, Sgambellone S, Masini E, McKenna R, et al. Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand/isoform matching and selectivity of action. J Med Chem. 2020;63(13):7422–7444.
   PubMed Web of Science ®Google Scholar